Pdb73 - Indirect Cost-Effectiveness Analysis of Empagliflozin Compared to Canagliflozin for Patients With T2dm and Cardiovascular Disease in the Spanish National Health Service

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.778
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pdb71 - Assessing the Relative Cost-Effectiveness of Empagliflozin and Canagliflozin for the Treatment of Type 2 Diabetes Patients With Existing Cardiovascular Disease in the Uk

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcv74 - Cost-Effectiveness Analysis of Rosuvastatin Compared to Atorvastatin in Spanish Patients at Moderate, High, and Very High Cardiovascular Risk

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Varenicline Compared to Placebo as an Aid to Smoking Cessation in Patients With Cardiovascular Disease

The Open Pharmacoeconomics & Health Economics Journal
2012English

Pdb76 - Cost-Effectiveness Analysis of Empagliflozin in Comparison to Liraglutide Based on Cardiovascular Outcome Trials

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Ce1 - Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcv51 - Cost Analysis of Safety Outcomes of Dabigatran vs. Warfarin in the Spanish National Health Service

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pdb54 - Estimated Events Avoided and Cost Offsets Associated With Using Canagliflozin to Treat Patients With Type Two Diabetes Mellitus (T2dm) With or at High Risk of Developing Cardiovascular Disease (Cvd) in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness Analysis of Atorvastatin Compared to Simvastatin in the Prevention of Cardiovascular Diseases in the Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Cost of the National Health Service

The Lancet
Medicine
1954English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy